Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Cardiovascular diseases

Nearly 30 million US adults could be taking aspirin for primary CVD prevention

Research has shown that nearly 30 million US adults may be taking daily aspirin for primary prevention of cardiovascular disease, despite evidence to show that the harms outweigh the benefits.

woman taking aspirin


Evidence shows that daily aspirin should not be used for the primary prevention of cardiovascular disease

Nearly 30 million adults without cardiovascular disease (CVD) in the United States could be at risk of harm from taking daily aspirin as a preventative medicine, research published in the Annals of Internal Medicine has indicated (23 July 2019)[1].

Researchers used responses from a 2017 health survey, which was nationally representative and included questions on self-reported aspirin use for CVD prevention from 14,328 adults aged 40 years and over.

They found that 23.4% of people reported taking daily aspirin for CVD prevention and, of these, 22.8% said they did so without a doctor’s recommendation. Nearly half of those aged 70 years and over reported taking aspirin, and over a quarter of adults who took aspirin had a history of peptic ulcer disease; aspirin use is not recommended for primary prevention of CVD in these two groups.

Evidence from three randomised controlled trials published in 2018 indicated that daily aspirin should not be used for the primary prevention of CVD as the harms, such as bleeding, outweighed the benefits. The researchers said their findings suggested around 29 million US adults without CVD could be taking daily aspirin as a preventative measure. 

“Our findings show a tremendous need for healthcare practitioners to enquire about ongoing aspirin use and to counsel patients about the balance of benefits and harms,” the team concluded.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207090

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.